Skip Navigation

Schizophrenia Bulletin 2003 29(3):541-546;
© 2003 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Silver, H.
Right arrow Articles by Kaplan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silver, H.
Right arrow Articles by Kaplan, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press

Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms

Henry Silver, MBBS, B MED SCI, D.P.M., FRANZCP, Nelson Aharon, M.D. and Alla Kaplan, M.D.
Director, Brain Behavior Laboratory, and Deputy Director, Sha'ar Menashe Mental Health Center Mobile Post Hefer, Israel; and Senior Lecturer, Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel
Psychiatrist, Flugelman (Mazra) Psychiatric Hospital Mobile Post Oshrat, Israel
Psychiatrist, Flugelman (Mazra) Psychiatric Hospital Mobile Post Oshrat, Israel

Send reprint requests to Henry Silver, Director, Brain Behavior Laboratory, and Deputy Director, Sha'ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel; e-mail: mdsilver{at}tx.technion.ac.il

Establishing that treatment for negative symptoms improves primary features of schizophrenia rather than similar symptoms of other etiology is an important clinical issue. Primary negative symptoms may also differ among themselves in the propensity to respond to a given treatment. In this study, we examined the response of negative symptoms to add-on fluvoxamine by analyzing discrete symptoms independently and controlling for potential confounding variables. Data from two published controlled studies comparing fluvoxamine to placebo were pooled for the analysis. Eleven of sixteen Scale for the Assessment of Negative Symptoms items tested, including key negative symptoms such as affective flattening and alogia, improved. The improvement was not related to base line levels of depressive, extrapyramidal, and positive symptoms or to changes in the symptom scores during the study. The findings support the view that fluvoxamine augmentation can improve primary negative symptoms in chronic schizophrenia patients.

Keywords: Side effects / SSRI / fluvoxamine / negative symptoms / response analysis / schizophrenia / augmentation treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Schizophr BullHome page
W. P Horan, A. M Kring, and J. J Blanchard
Anhedonia in Schizophrenia: A Review of Assessment Strategies
Schizophr Bull, April 1, 2006; 32(2): 259 - 273.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.